Neuropathic Pain in Cancer: What Are the Current Guidelines?

被引：8

作者：

Mulvey, Matthew R. ^{[1
]}

Paley, Carole A. ^{[1
]}

Schuberth, Anna ^{[1
]}

King, Natalie ^{[1
]}

Page, Andy ^{[2
]}

Neoh, Karen ^{[2
]}

机构：

[1] Univ Leeds, Sch Med, Leeds Inst Hlth Sci, Fac Med & Hlth, Level 10 Worsley Bldg,Clarendon Rd, Leeds LS2 9NL, W Yorkshire, England

[2] St Gemmas Hosp, Acad Unit Palliat Care, Leeds, England

来源：

CURRENT TREATMENT OPTIONS IN ONCOLOGY | 2024年

关键词：

Neuropathic cancer pain; Guidelines; Chronic pain; Treatment; Management; INDUCED PERIPHERAL NEUROPATHY; DOUBLE-BLIND; CLINICAL-PRACTICE; PHARMACOLOGICAL MANAGEMENT; PALLIATIVE MEDICINE; SCREENING TOOLS; EUROPEAN SURVEY; GRADING SYSTEM; PREVALENCE; SOCIETY;

D O I：

10.1007/s11864-024-01248-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neuropathic cancer pain is experienced by 30-40% of patients with cancer. It significantly reduces quality of life and overall wellbeing for patients living with and beyond cancer. The underlying mechanisms of neuropathic pain in patients with cancer are complex and involve direct tumour involvement, nerve compression or infiltration, chemotherapy and/or radiotherapy-induced nerve damage, or post-surgical complications. It is crucial for healthcare professionals to assess and manage neuropathic cancer pain effectively. There is increasing recognition that standardisation of neuropathic pain assessment leads to tailored management and improved patient outcomes. Pain management strategies, including medication, interventional analgesia, physical and complementary therapy, can help alleviate neuropathic pain and improve the patient's comfort and quality of life.

引用

页码：1193 / 1202

页数：10

共 93 条

[21] Prevalence of undertreatment in cancer pain. A review of published literature [J].